Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2021-07-08 00:00:00 ET · period of report 2021-07-06 · accession 0001209191-21-046030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-08 | 2021-07-06 | ABOS | Stalfort John A III | Dir | C - Cnv Deriv | — | +130.2K | 137.3K | +1,822% | — |
| DI | 2021-07-08 | 2021-07-06 | ABOS | Stalfort John A III | Dir | C - Cnv Deriv | — | +131.6K | 131.6K | New | — |
| D | 2021-07-08 | 2021-07-06 | ABOS | Stalfort John A III | Dir | P - Purchase | $16.00 | +35.0K | 172.3K | +25% | +$560.0K |
| DI | 2021-07-08 | 2021-07-06 | ABOS | Stalfort John A III | Dir | C - Cnv Deriv | $0.00 | -131.6K | 0 | -100% | $0 |
| D | 2021-07-08 | 2021-07-06 | ABOS | Stalfort John A III | Dir | C - Cnv Deriv | $0.00 | -130.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-06 | C | A | 130,180 | — | 137,324 | D See footnote | — | — | (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. |
| 2 | Common | Common Stock | 2021-07-06 | C | A | 131,595 | — | 131,595 | I | — | — | (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| 3 | Common | Common Stock | 2021-07-06 | P | A | 35,000 | $16.00 | 172,324 | D | — | — | |
| 4 | Derivative | Series B Preferred | 2021-07-06 | C | D | 131,595 | $0.00 | 0 | I | — · — to — | 131,595 Common Stock | (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| 5 | Derivative | Series A-1 Preferred | 2021-07-06 | C | D | 130,180 | $0.00 | 0 | D See footnote | — · — to — | 130,180 Common Stock | (F2) The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. (F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |